TickerSpark Feed

pharma

Everything tagged "pharma" across the TickerSpark archives.

Amgen (AMGN): Growth Drivers Offset Leverage Risk

Amgen is executing well as six growth drivers offset patent losses, but heavy leverage and a rich valuation keep the stock in Hold territory.

Sep 17, 2026·18 MIN

Healthcare Drug Manufacturers - General Biotech

Research ReportLLY

Eli Lilly (LLY): Growth Power Meets Premium Valuation

Eli Lilly is still one of the strongest growth stories in large-cap pharma, powered by tirzepatide and an expanding cardiometabolic pipeline. The stock remains constructive, but valuation now demands continued execution rather than multiple expansion.

Jul 4, 2026·19 MIN

Healthcare Drug Manufacturers - General Growth

OpinionMRK

Merck’s latest data may have bought it more time than bears want to admit

Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.

May 26, 2026·4 MIN

Healthcare Pharma Oncology

Research ReportAXSM

Axsome Therapeutics (AXSM): AUVELITY Drives a Premium Growth Story

Axsome has evolved into a commercial CNS growth story, led by AUVELITY’s rapid prescription gains and a newly expanded Alzheimer’s agitation opportunity. The stock looks attractive on execution, but valuation and ongoing losses keep it from being a low-risk idea.